Andrew Jack, pharmaceutical correspondent with the Financial Times, sits down with pharma industry communications specialist Mark Senak to discuss the FDA’s influence over approvals in Europe and whether the agency’s woes are affecting the European Medicines Agency (EMEA).
Listen: A Conversation With Financial Times’ Pharmaceutical Correspondent Andrew Jack